학술논문
Lewy body dementia: Overcoming barriers and identifying solutions.
Document Type
Academic Journal
Author
Agarwal K; The Boston Consulting Group, Boston, Massachusetts, USA.; Backler W; The Boston Consulting Group, Boston, Massachusetts, USA.; Bayram E; Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, California, USA.; Bloom L; Zag Bio, Inc, Cambridge, Massachusetts, USA.; Boeve BF; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.; Cha JH; Latus Bio, Cambridge, Massachusetts, USA.; Denslow M; Alzheimer Disease and Brain Health, Eisai, Inc., Nutley, New Jersey, USA.; Ferman TJ; Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida, USA.; Galasko D; Department of Neurosciences, and Shiley-Marcos Alzheimer's Disease Research Center, UC San Diego, La Jolla, California, USA.; Galvin JE; Department of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Boca Raton, Florida, USA.; Gomperts SN; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Irizarry MC; Alzheimer Disease and Brain Health, Eisai, Inc., Nutley, New Jersey, USA.; Kantarci K; Department of Radiology, Division of Neuroradiology, Mayo Clinic Rochester, Rochester, Minnesota, USA.; Kaushik H; The Boston Consulting Group, Boston, Massachusetts, USA.; Kietlinski M; The Boston Consulting Group, Boston, Massachusetts, USA.; Koenig A; Delix Therapeutics, Bedford, Massachusetts, USA.; Leverenz JB; Cleveland Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.; McKeith I; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; McLean PJ; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.; Montine TJ; Department of Pathology, Stanford University, Stanford, California, USA.; Moose SO; The Boston Consulting Group, Boston, Massachusetts, USA.; O'Brien JT; Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.; Panier V; The Boston Consulting Group, Boston, Massachusetts, USA.; Ramanathan S; Departments of Molecular and Cell Biology, Stem Cell and Regenerative Biology and Applied Physics, Harvard University, Cambridge, Massachusetts, USA.; Ringel MS; The Boston Consulting Group, Boston, Massachusetts, USA.; Scholz SW; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.; Department of Neurology, Johns Hopkins University Medical Center, Baltimore, Maryland, USA.; Small J; The Boston Consulting Group, Boston, Massachusetts, USA.; Sperling RA; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Taylor A; Lewy Body Dementia Association, Lilburn, Georgia, USA.; Taylor JP; Department of Pathology, Stanford University, Stanford, California, USA.; Ward RA; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.; Witten L; The Boston Consulting Group, Boston, Massachusetts, USA.; Hyman BT; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Source
Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE
Subject
Language
English
Abstract
Despite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public-health burden that LBD imposes is worsened by overlapping pathologies, which contribute to misdiagnosis, and lack of treatments. For this report, we gathered and analyzed public-domain information on advocacy, funding, research outputs, and the therapeutic pipeline to identify gaps in each of these key elements. To further understand the current gaps, we also conducted interviews with leading experts in regulatory/governmental agencies, LBD advocacy, academic research, and biopharmaceutical research, as well as with funding sources. We identified wide gaps across the entire landscape, the most critical being in research. Many of the experts participated in a workshop to discuss the prioritization of research areas with a view to accelerating therapeutic development and improving patient care. This white paper outlines the opportunities for bridging the major LBD gaps and creates the framework for collaboration in that endeavor. HIGHLIGHTS: A group representing academia, government, industry, and consulting expertise was convened to discuss current progress in Dementia with Lewy Body care and research. Consideration of expert opinion,natural language processing of the literature as well as publicly available data bases, and Delphi inspired discussion led to a proposed consensus document of priorities for the field.
(© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
(© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)